RegulatoryCompany release

FDA grants priority review to Dyne's z-rostudirsen for exon 51 Duchenne; decision due 21 January 2027

🇺🇸 Dyne Therapeutics, Inc. (DYN) · Thu 05 Nov 2026

Dyne Therapeutics reports a PDUFA date for its Duchenne muscular dystrophy BLA alongside one-year myotonic dystrophy data, a wider third-quarter loss and a cash runway into Q2 2028.

Dyne Therapeutics said on 5 November 2026 that the US Food and Drug Administration has accepted its biologics licence application (BLA) for z-rostudirsen for priority review. The product is intended for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping. The agency has set a PDUFA action date of 21 January 2027.

In the same update, the company reported one-year data from the Phase 1/2 ACHIEVE study of z-basivarsen in myotonic dystrophy type 1. Dyne expects to report topline data from the registrational cohort of that programme in the first quarter of 2027.

On the financial side, Dyne posted a third-quarter net loss of $193.6 million, which it described as wider than before. Cash stood at $1.134 billion, which the company expects to fund operations into the second quarter of 2028.

For context, priority review is an FDA designation that aims to shorten the target review period for therapies that may offer significant improvements in treating serious conditions. A PDUFA date is the goal date by which the agency aims to complete its review of an application.

What it means for your team

  • Regulatory teams tracking Duchenne should note 21 January 2027 as the FDA action date for z-rostudirsen in exon 51 disease.
  • Market-access planners in the exon-skipping field may want to follow the review outcome, as it will determine whether a new exon 51 option reaches the US market.
  • The first-quarter 2027 topline readout for z-basivarsen in myotonic dystrophy type 1 is the next clinical milestone for the company's second programme.
  • The stated cash runway into Q2 2028 covers the period around the PDUFA date and the registrational readout.

Company's press release (SEC filing): Dyne Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Dyne Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →